{"url_path":"/sec/cntx/8-k/2026-05-18/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-18","source_url":"https://www.sec.gov/Archives/edgar/data/1842952/0001628280-26-035793-index.html","accession_number":"0001628280-26-035793","cik":"0001842952","ticker":"CNTX","issuer_name":"Context Therapeutics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1842952/0001628280-26-035793-index.html","primary_entity_key":"0001842952","primary_entity_name":"Context Therapeutics Inc."},"word_count":114,"has_tables":true,"body_markdown":"Item 7.01. Regulation FD Disclosure.\n\nOn May 18, 2026, the Company issued a press release announcing the Amendment. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.\n\nThe information in this Item 7.01, and Exhibit 99.1 attached hereto, are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing."}